Suscribirse

Intravenous Acyclovir and Renal Dysfunction in Children: A Matched Case Control Study - 24/05/15

Doi : 10.1016/j.jpeds.2015.01.023 
Suchitra Rao, MBBS 1, , Mark J. Abzug, MD 1, Phyllis Carosone-Link, MS, MSPH 1, Tori Peterson, PharmD 2, Jason Child, PharmD 2, Georgette Siparksy, PhD 3, Danielle Soranno, MD 4, Melissa A. Cadnapaphornchai, MD 4, Eric A.F. Simões, MBBS, DCH, MD 1, 5
1 Department of Pediatrics (Infectious Diseases and Hospital Medicine), University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO 
2 Department of Pharmacy, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO 
3 Department of Clinical Informatics, Children's Hospital of Colorado, Aurora, CO 
4 Section of Nephrology, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO 
5 Department of Epidemiology, Colorado School of Public Health and Children's Hospital Colorado, Aurora, CO 

Reprint requests: Suchitra Rao, MBBS, Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children's Hospital Colorado, Box 055, 13123 E. 16th Ave, Aurora, CO 80045.

Abstract

Objectives

A cluster of children receiving intravenous (IV) acyclovir for meningoencephalitis developed acute renal failure in April-May 2008, which prompted a retrospective case-control study to determine the rate of and risk factors for acute nephrotoxicity during IV acyclovir treatment in children.

Study design

The percentage decrease in glomerular filtration rate in children receiving IV acyclovir who had ≥1 creatinine measurement after acyclovir initiation from October 2006 to January 2009 was classified as renal risk, injury, or failure according to modified Pediatric Risk Injury, Failure, Loss, End-Stage Renal Disease criteria. Univariate and multivariate matched analyses were conducted to identify risk factors contributing to nephrotoxicity.

Results

In the selected study group, renal dysfunction was seen in 131 of 373 (35%) treatment courses studied: 81 of 373 (22%) risk, 36 of 373 (9.7%) injury, and 14 of 373 (3.8%) failure. Most renal dysfunction occurred within 48 hours of the initiation of acyclovir. Renal function returned to the normal range but not to baseline in most cases during the follow-up period. Risk factors for renal dysfunction included acyclovir dose >15 mg/kg (OR 3.81, 95% CI 1.55-9.37) for risk; cumulative exposure greater than calculated cumulative exposure based on 500 mg/m2/dose (OR 6.00, 95% CI 1.95-18.46) for injury; and age >8 years (OR 21.5, 95% CI 2.2, >1000) and ceftriaxone coadministration (OR 19.3, 95% CI 1.8, >1000) for failure.

Conclusions

Nephrotoxicity associated with IV acyclovir is common and necessitates renal function monitoring. Risk factors include greater dose, older age, and concomitant ceftriaxone administration. Outside the neonatal period, renal dysfunction may be minimized by dosing IV acyclovir below thresholds associated with nephrotoxicity (ie, ≤500 mg/m2/dose or ≤15 mg/kg/dose), particularly in older patients.

El texto completo de este artículo está disponible en PDF.

Keyword : BMI, eGFR, HSV, IV, sCr, VZV, Δdose500


Esquema


 The authors declare no conflicts of interest.


© 2015  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 166 - N° 6

P. 1462 - juin 2015 Regresar al número
Artículo precedente Artículo precedente
  • Treatment of Methylmalonic Acidemia by Liver or Combined Liver-Kidney Transplantation
  • Anna-Kaisa Niemi, Irene K. Kim, Casey E. Krueger, Tina M. Cowan, Nancy Baugh, Rachel Farrell, Clark A. Bonham, Waldo Concepcion, Carlos O. Esquivel, Gregory M. Enns
| Artículo siguiente Artículo siguiente
  • Long-Term Outcomes of Children with Intermediate Sweat Chloride Values in Infancy
  • Tyler Groves, Paul Robinson, Veronica Wiley, Dominic A. Fitzgerald

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.